As reported in JAMA Network Open , the study was carried out across 28 hospitals in China and included 278 patients who were receiving immunotherapy, most commonly for gastric, esophageal, or lung cancer.

The week beginning 15 March also saw a significant decrease in genetic consultations, with a 29.1% fall in consultations compared with the previous week (from 392 to 278 consultations).

In the phase 3 study, pembrolizumab 200 mg or placebo was administered to 278 and 280 patients, respectively, in addition to carboplatin plus paclitaxel or nab-paclitaxel every 3 weeks for 4 cycles, after which pembrolizumab or placebo were administered alone for 31 remaining cycles.

In the second interim analysis – conducted at a median follow-up of 7.8 months – the co-primary endpoint of overall survival was a median of 15.9 months for the 278 participants who were randomly assigned to receive pembrolizumab 200 mg for up to 35 cycles alongside carboplatin plus paclitaxel or nanoparticle albumin-bound (nab)-paclitaxel for the first four cycles.

In total, 834 patients with advanced melanoma were enrolled into the multicenter KEYNOTE-006 study and randomly assigned to receive treatment with intravenous pembrolizumab 10 mg/kg every 2 weeks (n=279) or every 3 weeks (n=277) for a maximum of 2 years, or to receive intravenous ipilimumab 3 mg/kg every 3 weeks for four doses (n=278).

Analysis using an 18-gene, T-cell inflamed, gene expression profile (GEP) of pretreatment samples of 278 patients showed that those who responded to treatment had a significantly higher score than nonresponders.

Indeed, 7% of 271 patients in the CT-P6 group reported serious treatment-emergent adverse events compared with 8% of 278 in the reference trastuzumab group.

In the double-blind FRESCO (Fruquintinib Efficacy and Safety in 3+ Line Colorectal Cancer Patients) study of patients who had progressed after at least two lines of chemotherapy, OS was a median of 9.3 months for the 278 patients who were randomly assigned to receive the highly selective inhibitor of VEGFR-1, 2, and 3 at a dose of 5 mg/day for 21 days of each 28-day cycle.